Skip to main content
Top
Published in: International Urology and Nephrology 4/2017

01-04-2017 | Urology - Original Paper

Antimicrobial activity Study of triclosan-loaded WBPU on Proteus mirabilis in vitro

Authors: Ye Tian, Zhongyu Jian, Jianzhong Wang, Wei He, Qinyu Liu, Kunjie Wang, Hong Li, Hong Tan

Published in: International Urology and Nephrology | Issue 4/2017

Login to get access

Abstract

Objectives

To evaluate the antimicrobial activity study of triclosan-loaded waterborne polyurethanes (WBPU) on Proteus mirabilis in vitro.

Materials and methods

Inhibition zone assays on petri plates with triclosan-loaded WBPU samples were used to test its antimicrobial activity on Proteus mirabilis. Models of the catheterized bladder supplied with artificial urine infected with Proteus mirabilis were employed to confirm the antimicrobial activity of triclosan-loaded WBPU. Bacteria colony counting, pH of the residual urine at each time point and catheter blockage time were recorded. Confocal laser scanning microscopy, scanning electron microscopy and encrustation deposits dry weighing were used for evaluating the biofilm formation.

Results

Inhibition zones formed in the triclosan-loaded WBPU groups in a dose–response manner (the radius for samples with 1, 0.1 and 0.01 mg triclosan were 9.93 ± 1.08, 6.07 ± 0.54 and 2.47 ± 0.25 mm, P < 0.001). The bacterial growth in the triclosan group was markedly inhibited, which was almost undetectable after 12 h of bladder running. Residual urine pH in the control group increased significantly in comparison with the triclosan group (9.50 ± 0.04 vs. 6.17 ± 0.01 at 24 h, P < 0.001). The presence of triclosan-loaded WBPU decreased catheter encrustations and markedly postponed the catheter blockage time, as well as suppressed the Proteus mirabilis biofilm formation (33.9 ± 13.9 mg vs. 1.4 ± 1.5 mg, P = 0.016).

Conclusions

Triclosan-loaded WBPU significantly inhibited Proteus mirabilis’ growth and biofilm formation, indicating the promising antibacterial effects on Proteus mirabilis in vitro. Further efforts are under way that involves coating the material onto the urinary catheters and in vivo studies.
Literature
1.
go back to reference Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, Mcallister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK (2014) Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370:1198–1208CrossRefPubMedPubMedCentral Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, Mcallister-Hollod L, Nadle J, Ray SM, Thompson DL, Wilson LE, Fridkin SK (2014) Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370:1198–1208CrossRefPubMedPubMedCentral
2.
go back to reference Zarb P, Coignard B, Griskeviciene J, Muller A, Vankerckhoven V, Weist K, Goossens M, Vaerenberg S, Hopkins S, Catry B, Monnet D, Goossens H, Suetens C (2012) The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill 17:1–16 Zarb P, Coignard B, Griskeviciene J, Muller A, Vankerckhoven V, Weist K, Goossens M, Vaerenberg S, Hopkins S, Catry B, Monnet D, Goossens H, Suetens C (2012) The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill 17:1–16
3.
go back to reference Burton DC, Edwards JR, Srinivasan A, Fridkin SK, Gould CV (2011) Trends in catheter-associated urinary tract infections in adult intensive care units-United States, 1990–2007. Infect Control Hosp Epidemiol 32:748–756CrossRefPubMed Burton DC, Edwards JR, Srinivasan A, Fridkin SK, Gould CV (2011) Trends in catheter-associated urinary tract infections in adult intensive care units-United States, 1990–2007. Infect Control Hosp Epidemiol 32:748–756CrossRefPubMed
4.
go back to reference Stickler DJ (2008) Bacterial biofilms in patients with indwelling urinary catheters. Nat Clin Pract Urol 5:598–608CrossRefPubMed Stickler DJ (2008) Bacterial biofilms in patients with indwelling urinary catheters. Nat Clin Pract Urol 5:598–608CrossRefPubMed
5.
go back to reference Lazar V, Chifiriuc MC (2010) Medical significance and new therapeutical strategies for biofilm associated infections. Roum Arch Microbiol Immunol 69:125–138PubMed Lazar V, Chifiriuc MC (2010) Medical significance and new therapeutical strategies for biofilm associated infections. Roum Arch Microbiol Immunol 69:125–138PubMed
6.
go back to reference Koseoglu H, Aslan G, Esen N, Sen BH, Coban H (2006) Ultrastructural stages of biofilm development of Escherichia coli on urethral catheters and effects of antibiotics on biofilm formation. Urology 68:942–946CrossRefPubMed Koseoglu H, Aslan G, Esen N, Sen BH, Coban H (2006) Ultrastructural stages of biofilm development of Escherichia coli on urethral catheters and effects of antibiotics on biofilm formation. Urology 68:942–946CrossRefPubMed
7.
go back to reference Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: a common cause of persistent infections. Science 284:1318–1322CrossRefPubMed Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: a common cause of persistent infections. Science 284:1318–1322CrossRefPubMed
8.
go back to reference Tenke P, Kovacs B, Jackel M, Nagy E (2006) The role of biofilm infection in urology. World J Urol 24:13–20CrossRefPubMed Tenke P, Kovacs B, Jackel M, Nagy E (2006) The role of biofilm infection in urology. World J Urol 24:13–20CrossRefPubMed
9.
go back to reference Tenke P, Koves B, Nagy K, Hultgren SJ, Mendling W, Wullt B, Grabe M, Wagenlehner FM, Cek M, Pickard R, Botto H, Naber KG, Bjerklund JT (2012) Update on biofilm infections in the urinary tract. World J Urol 30:51–57CrossRefPubMed Tenke P, Koves B, Nagy K, Hultgren SJ, Mendling W, Wullt B, Grabe M, Wagenlehner FM, Cek M, Pickard R, Botto H, Naber KG, Bjerklund JT (2012) Update on biofilm infections in the urinary tract. World J Urol 30:51–57CrossRefPubMed
10.
go back to reference Ward WH, Holdgate GA, Rowsell S, Mclean EG, Pauptit RA, Clayton E, Nichols WW, Colls JG, Minshull CA, Jude DA, Mistry A, Timms D, Camble R, Hales NJ, Britton CJ, Taylor IW (1999) Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 38:12514–12525CrossRefPubMed Ward WH, Holdgate GA, Rowsell S, Mclean EG, Pauptit RA, Clayton E, Nichols WW, Colls JG, Minshull CA, Jude DA, Mistry A, Timms D, Camble R, Hales NJ, Britton CJ, Taylor IW (1999) Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan. Biochemistry 38:12514–12525CrossRefPubMed
11.
go back to reference Macocinschi D, Filip D, Vlad S, Cristea M, Butnaru M (2009) Segmented biopolyurethanes for medical applications. J Mater Sci Mater Med 20:1659–1668CrossRefPubMed Macocinschi D, Filip D, Vlad S, Cristea M, Butnaru M (2009) Segmented biopolyurethanes for medical applications. J Mater Sci Mater Med 20:1659–1668CrossRefPubMed
12.
go back to reference Santerre JP, Woodhouse K, Laroche G, Labow RS (2005) Understanding the biodegradation of polyurethanes: from classical implants to tissue engineering materials. Biomaterials 26:7457–7470CrossRefPubMed Santerre JP, Woodhouse K, Laroche G, Labow RS (2005) Understanding the biodegradation of polyurethanes: from classical implants to tissue engineering materials. Biomaterials 26:7457–7470CrossRefPubMed
13.
go back to reference Jiang X, Li J, Ding M, Tan H, Ling Q, Zhong Y, Fu Q (2007) Synthesis and degradation of nontoxic biodegradable waterborne polyurethanes elastomer with poly(ε-caprolactone) and poly(ethylene glycol) as soft segment. Eur Polymer J 43:1838–1846CrossRef Jiang X, Li J, Ding M, Tan H, Ling Q, Zhong Y, Fu Q (2007) Synthesis and degradation of nontoxic biodegradable waterborne polyurethanes elastomer with poly(ε-caprolactone) and poly(ethylene glycol) as soft segment. Eur Polymer J 43:1838–1846CrossRef
14.
go back to reference Griffith DP, Musher DM, Itin C (1976) Urease. The primary cause of infection-induced urinary stones. Invest Urol 13:346–350PubMed Griffith DP, Musher DM, Itin C (1976) Urease. The primary cause of infection-induced urinary stones. Invest Urol 13:346–350PubMed
15.
go back to reference Tian Y, Cai X, Wazir R, Wang K, Li H (2016) Water consumption and urinary tract infections: an in vitro study. Int Urol Nephrol 48:949–954CrossRefPubMed Tian Y, Cai X, Wazir R, Wang K, Li H (2016) Water consumption and urinary tract infections: an in vitro study. Int Urol Nephrol 48:949–954CrossRefPubMed
16.
go back to reference Wang J, Liu Q, Tian Y, Jian Z, Li H, Wang K (2015) Biodegradable hydrophilic polyurethane PEGU25 loading antimicrobial peptide Bmap-28: a sustained-release membrane able to inhibit bacterial biofilm formation in vitro. Sci Rep 5:8634CrossRefPubMedPubMedCentral Wang J, Liu Q, Tian Y, Jian Z, Li H, Wang K (2015) Biodegradable hydrophilic polyurethane PEGU25 loading antimicrobial peptide Bmap-28: a sustained-release membrane able to inhibit bacterial biofilm formation in vitro. Sci Rep 5:8634CrossRefPubMedPubMedCentral
17.
go back to reference Jacobsen SM, Stickler DJ, Mobley HL, Shirtliff ME (2008) Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev 21:26–59CrossRefPubMedPubMedCentral Jacobsen SM, Stickler DJ, Mobley HL, Shirtliff ME (2008) Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin Microbiol Rev 21:26–59CrossRefPubMedPubMedCentral
18.
19.
go back to reference Stickler DJ, Zimakoff J (1994) Complications of urinary tract infections associated with devices used for long-term bladder management. J Hosp Infect 28:177–194CrossRefPubMed Stickler DJ, Zimakoff J (1994) Complications of urinary tract infections associated with devices used for long-term bladder management. J Hosp Infect 28:177–194CrossRefPubMed
20.
go back to reference Donlan RM (2011) Biofilm elimination on intravascular catheters: important considerations for the infectious disease practitioner. Clin Infect Dis 52:1038–1045CrossRefPubMed Donlan RM (2011) Biofilm elimination on intravascular catheters: important considerations for the infectious disease practitioner. Clin Infect Dis 52:1038–1045CrossRefPubMed
21.
go back to reference Foxman B, Wu J, Farrer EC, Goldberg DE, Younger JG, Xi C (2012) Early development of bacterial community diversity in emergently placed urinary catheters. BMC Res Notes 5:332CrossRefPubMedPubMedCentral Foxman B, Wu J, Farrer EC, Goldberg DE, Younger JG, Xi C (2012) Early development of bacterial community diversity in emergently placed urinary catheters. BMC Res Notes 5:332CrossRefPubMedPubMedCentral
22.
go back to reference Schumm K, Lam TB (2008) Types of urethral catheters for management of short-term voiding problems in hospitalised adults. Cochrane Database Syst Rev 2:CD004013 Schumm K, Lam TB (2008) Types of urethral catheters for management of short-term voiding problems in hospitalised adults. Cochrane Database Syst Rev 2:CD004013
23.
go back to reference Bondarenko O, Juganson K, Ivask A, Kasemets K, Mortimer M, Kahru A (2013) Toxicity of Ag, CuO and ZnO nanoparticles to selected environmentally relevant test organisms and mammalian cells in vitro: a critical review. Arch Toxicol 87:1181–1200CrossRefPubMedPubMedCentral Bondarenko O, Juganson K, Ivask A, Kasemets K, Mortimer M, Kahru A (2013) Toxicity of Ag, CuO and ZnO nanoparticles to selected environmentally relevant test organisms and mammalian cells in vitro: a critical review. Arch Toxicol 87:1181–1200CrossRefPubMedPubMedCentral
24.
go back to reference Pickard R, Lam T, Maclennan G, Starr K, Kilonzo M, Mcpherson G, Gillies K, Mcdonald A, Walton K, Buckley B, Glazener C, Boachie C, Burr J, Norrie J, Vale L, Grant A, N’Dow J (2012) Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial. Lancet 380:1927–1935CrossRefPubMed Pickard R, Lam T, Maclennan G, Starr K, Kilonzo M, Mcpherson G, Gillies K, Mcdonald A, Walton K, Buckley B, Glazener C, Boachie C, Burr J, Norrie J, Vale L, Grant A, N’Dow J (2012) Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial. Lancet 380:1927–1935CrossRefPubMed
25.
go back to reference Regev-Shoshani G, Ko M, Crowe A, Av-Gay Y (2011) Comparative efficacy of commercially available and emerging antimicrobial urinary catheters against bacteriuria caused by E. Coli in vitro. Urology 78:334–339CrossRefPubMed Regev-Shoshani G, Ko M, Crowe A, Av-Gay Y (2011) Comparative efficacy of commercially available and emerging antimicrobial urinary catheters against bacteriuria caused by E. Coli in vitro. Urology 78:334–339CrossRefPubMed
26.
go back to reference Pickard R, Lam T, Maclennan G, Starr K, Kilonzo M, Mcpherson G, Gillies K, Mcdonald A, Walton K, Buckley B, Glazener C, Boachie C, Burr J, Norrie J, Vale L, Grant A, N’Dow J (2012) Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-term catheterisation: multicentre randomised controlled trial and economic evaluation of antimicrobial- and antiseptic-impregnated urethral catheters (the CATHETER trial). Health Technol Assess 16:1–197CrossRefPubMedCentral Pickard R, Lam T, Maclennan G, Starr K, Kilonzo M, Mcpherson G, Gillies K, Mcdonald A, Walton K, Buckley B, Glazener C, Boachie C, Burr J, Norrie J, Vale L, Grant A, N’Dow J (2012) Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-term catheterisation: multicentre randomised controlled trial and economic evaluation of antimicrobial- and antiseptic-impregnated urethral catheters (the CATHETER trial). Health Technol Assess 16:1–197CrossRefPubMedCentral
28.
go back to reference Shapur NK, Duvdevani M, Friedman M, Zaks B, Gati I, Lavy E, Katz R, Landau EH, Pode D, Gofrit ON, Steinberg D (2012) Sustained release varnish containing chlorhexidine for prevention of biofilm formation on urinary catheter surface: in vitro study. J Endourol 26:26–31CrossRefPubMed Shapur NK, Duvdevani M, Friedman M, Zaks B, Gati I, Lavy E, Katz R, Landau EH, Pode D, Gofrit ON, Steinberg D (2012) Sustained release varnish containing chlorhexidine for prevention of biofilm formation on urinary catheter surface: in vitro study. J Endourol 26:26–31CrossRefPubMed
29.
go back to reference Norton RE, Patole S, Whitehall J (2001) An in vitro study of the efficacy of rifampicin and minocycline coated umbilical venous catheters. Int J Antimicrob Agents 17:237–240CrossRefPubMed Norton RE, Patole S, Whitehall J (2001) An in vitro study of the efficacy of rifampicin and minocycline coated umbilical venous catheters. Int J Antimicrob Agents 17:237–240CrossRefPubMed
30.
go back to reference Kowalczuk D, Ginalska G, Piersiak T, Miazga-Karska M (2012) Prevention of biofilm formation on urinary catheters: comparison of the sparfloxacin-treated long-term antimicrobial catheters with silver-coated ones. J Biomed Mater Res B Appl Biomater 100:1874–1882CrossRefPubMed Kowalczuk D, Ginalska G, Piersiak T, Miazga-Karska M (2012) Prevention of biofilm formation on urinary catheters: comparison of the sparfloxacin-treated long-term antimicrobial catheters with silver-coated ones. J Biomed Mater Res B Appl Biomater 100:1874–1882CrossRefPubMed
31.
go back to reference Cho YH, Lee SJ, Lee JY, Kim SW, Kwon IC, Chung SY, Yoon MS (2001) Prophylactic efficacy of a new gentamicin-releasing urethral catheter in short-term catheterized rabbits. BJU Int 87:104–109CrossRefPubMed Cho YH, Lee SJ, Lee JY, Kim SW, Kwon IC, Chung SY, Yoon MS (2001) Prophylactic efficacy of a new gentamicin-releasing urethral catheter in short-term catheterized rabbits. BJU Int 87:104–109CrossRefPubMed
32.
go back to reference Makuta G, Chrysafis M, Lam T (2013) Measuring the efficacy of antimicrobial catheters. Nurs Times 109:18–19 Makuta G, Chrysafis M, Lam T (2013) Measuring the efficacy of antimicrobial catheters. Nurs Times 109:18–19
33.
go back to reference Srinivasan A, Karchmer T, Richards A, Song X, Perl TM (2006) A prospective trial of a novel, silicone-based, silver-coated foley catheter for the prevention of nosocomial urinary tract infections. Infect Control Hosp Epidemiol 27:38–43CrossRefPubMed Srinivasan A, Karchmer T, Richards A, Song X, Perl TM (2006) A prospective trial of a novel, silicone-based, silver-coated foley catheter for the prevention of nosocomial urinary tract infections. Infect Control Hosp Epidemiol 27:38–43CrossRefPubMed
34.
go back to reference Moss T, Howes D, Williams FM (2000) Percutaneous penetration and dermal metabolism of triclosan (2,4, 4′-trichloro-2′-hydroxydiphenyl ether). Food Chem Toxicol 38:361–370CrossRefPubMed Moss T, Howes D, Williams FM (2000) Percutaneous penetration and dermal metabolism of triclosan (2,4, 4′-trichloro-2′-hydroxydiphenyl ether). Food Chem Toxicol 38:361–370CrossRefPubMed
35.
go back to reference Mustafa M, Wondimu B, Yucel-Lindberg T, Kats-Hallstrom AT, Jonsson AS, Modeer T (2005) Triclosan reduces microsomal prostaglandin E synthase-1 expression in human gingival fibroblasts. J Clin Periodontol 32:6–11CrossRefPubMed Mustafa M, Wondimu B, Yucel-Lindberg T, Kats-Hallstrom AT, Jonsson AS, Modeer T (2005) Triclosan reduces microsomal prostaglandin E synthase-1 expression in human gingival fibroblasts. J Clin Periodontol 32:6–11CrossRefPubMed
36.
go back to reference Xu T, Deshmukh M, Barnes VM, Trivedi HM, Cummins D (2004) Effectiveness of a triclosan/copolymer dentifrice on microbiological and inflammatory parameters. Compend Contin Educ Dent 25:46–53PubMed Xu T, Deshmukh M, Barnes VM, Trivedi HM, Cummins D (2004) Effectiveness of a triclosan/copolymer dentifrice on microbiological and inflammatory parameters. Compend Contin Educ Dent 25:46–53PubMed
37.
go back to reference Mendez-Probst CE, Goneau LW, Macdonald KW, Nott L, Seney S, Elwood CN, Lange D, Chew BH, Denstedt JD, Cadieux PA (2012) The use of triclosan eluting stents effectively reduces ureteral stent symptoms: a prospective randomized trial. BJU Int 110:749–754CrossRefPubMed Mendez-Probst CE, Goneau LW, Macdonald KW, Nott L, Seney S, Elwood CN, Lange D, Chew BH, Denstedt JD, Cadieux PA (2012) The use of triclosan eluting stents effectively reduces ureteral stent symptoms: a prospective randomized trial. BJU Int 110:749–754CrossRefPubMed
38.
go back to reference Chew BH, Lange D (2009) Ureteral stent symptoms and associated infections: a biomaterials perspective. Nat Rev Urol 6:440–448CrossRefPubMed Chew BH, Lange D (2009) Ureteral stent symptoms and associated infections: a biomaterials perspective. Nat Rev Urol 6:440–448CrossRefPubMed
39.
go back to reference Russell AD (2003) Biocide use and antibiotic resistance: the relevance of laboratory findings to clinical and environmental situations. Lancet Infect Dis 3:794–803CrossRefPubMed Russell AD (2003) Biocide use and antibiotic resistance: the relevance of laboratory findings to clinical and environmental situations. Lancet Infect Dis 3:794–803CrossRefPubMed
41.
go back to reference Ledder RG, Gilbert P, Willis C, Mcbain AJ (2006) Effects of chronic triclosan exposure upon the antimicrobial susceptibility of 40 ex situ environmental and human isolates. J Appl Microbiol 100:1132–1140CrossRefPubMed Ledder RG, Gilbert P, Willis C, Mcbain AJ (2006) Effects of chronic triclosan exposure upon the antimicrobial susceptibility of 40 ex situ environmental and human isolates. J Appl Microbiol 100:1132–1140CrossRefPubMed
42.
go back to reference Mcbain AJ, Bartolo RG, Catrenich CE, Charbonneau D, Ledder RG, Price BB, Gilbert P (2003) Exposure of sink drain microcosms to triclosan: population dynamics and antimicrobial susceptibility. Appl Environ Microbiol 69:5433–5442CrossRefPubMedPubMedCentral Mcbain AJ, Bartolo RG, Catrenich CE, Charbonneau D, Ledder RG, Price BB, Gilbert P (2003) Exposure of sink drain microcosms to triclosan: population dynamics and antimicrobial susceptibility. Appl Environ Microbiol 69:5433–5442CrossRefPubMedPubMedCentral
43.
go back to reference Mcbain AJ, Ledder RG, Sreenivasan P, Gilbert P (2004) Selection for high-level resistance by chronic triclosan exposure is not universal. J Antimicrob Chemother 53:772–777CrossRefPubMed Mcbain AJ, Ledder RG, Sreenivasan P, Gilbert P (2004) Selection for high-level resistance by chronic triclosan exposure is not universal. J Antimicrob Chemother 53:772–777CrossRefPubMed
44.
go back to reference Cadieux PA, Chew BH, Nott L, Seney S, Elwood CN, Wignall GR, Goneau LW, Denstedt JD (2009) Use of triclosan-eluting ureteral stents in patients with long-term stents. J Endourol 23:1187–1194CrossRefPubMed Cadieux PA, Chew BH, Nott L, Seney S, Elwood CN, Wignall GR, Goneau LW, Denstedt JD (2009) Use of triclosan-eluting ureteral stents in patients with long-term stents. J Endourol 23:1187–1194CrossRefPubMed
45.
go back to reference Stickler DJ (2002) Susceptibility of antibiotic-resistant Gram-negative bacteria to biocides: a perspective from the study of catheter biofilms. J Appl Microbiol 92:163S–170SCrossRefPubMed Stickler DJ (2002) Susceptibility of antibiotic-resistant Gram-negative bacteria to biocides: a perspective from the study of catheter biofilms. J Appl Microbiol 92:163S–170SCrossRefPubMed
Metadata
Title
Antimicrobial activity Study of triclosan-loaded WBPU on Proteus mirabilis in vitro
Authors
Ye Tian
Zhongyu Jian
Jianzhong Wang
Wei He
Qinyu Liu
Kunjie Wang
Hong Li
Hong Tan
Publication date
01-04-2017
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2017
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-017-1532-z

Other articles of this Issue 4/2017

International Urology and Nephrology 4/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine